Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID-19) worldwide. Wuhan, a city in China became the epicenter of the outbreak of COVID-19 in December 2019. The disease was declared...

Full description

Bibliographic Details
Main Authors: Uttpal Anand, Shweta Jakhmola, Omkar Indari, Hem Chandra Jha, Zhe-Sheng Chen, Vijay Tripathi, José M. Pérez de la Lastra
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.658519/full
id doaj-56b0779b74c843e8bf46c65291cac1a2
record_format Article
spelling doaj-56b0779b74c843e8bf46c65291cac1a22021-06-30T07:00:50ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-06-011210.3389/fimmu.2021.658519658519Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent UpdateUttpal Anand0Shweta Jakhmola1Omkar Indari2Hem Chandra Jha3Zhe-Sheng Chen4Vijay Tripathi5José M. Pérez de la Lastra6Department of Life Sciences, National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, IsraelDiscipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, IndiaDiscipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, IndiaDiscipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, IndiaDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, United StatesDepartment of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, IndiaInstituto de Productos Naturales y Agrobiología (IPNA), Consejo Superior de Investigaciones científicas (CSIS), Santa Cruz de Tenerife, SpainSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID-19) worldwide. Wuhan, a city in China became the epicenter of the outbreak of COVID-19 in December 2019. The disease was declared a pandemic globally by the World Health Organization (WHO) on 11 March 2020. SARS-CoV-2 is a beta CoV of the Coronaviridae family which usually causes respiratory symptoms that resemble common cold. Multiple countries have experienced multiple waves of the disease and scientific experts are consistently working to find answers to several unresolved questions, with the aim to find the most suitable ways to contain the virus. Furthermore, potential therapeutic strategies and vaccine development for COVID-19 management are also considered. Currently, substantial efforts have been made to develop successful and safe treatments and SARS-CoV-2 vaccines. Some vaccines, such as inactivated vaccines, nucleic acid-based, and vector-based vaccines, have entered phase 3 clinical trials. Additionally, diverse small molecule drugs, peptides and antibodies are being developed to treat COVID-19. We present here an overview of the virus interaction with the host and environment and anti-CoV therapeutic strategies; including vaccines and other methodologies, designed for prophylaxis and treatment of SARS-CoV-2 infection with the hope that this integrative analysis could help develop novel therapeutic approaches against COVID-19.https://www.frontiersin.org/articles/10.3389/fimmu.2021.658519/fullCOVID-19vaccinetherapeutic targetspeptideantibodiestreatment
collection DOAJ
language English
format Article
sources DOAJ
author Uttpal Anand
Shweta Jakhmola
Omkar Indari
Hem Chandra Jha
Zhe-Sheng Chen
Vijay Tripathi
José M. Pérez de la Lastra
spellingShingle Uttpal Anand
Shweta Jakhmola
Omkar Indari
Hem Chandra Jha
Zhe-Sheng Chen
Vijay Tripathi
José M. Pérez de la Lastra
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
Frontiers in Immunology
COVID-19
vaccine
therapeutic targets
peptide
antibodies
treatment
author_facet Uttpal Anand
Shweta Jakhmola
Omkar Indari
Hem Chandra Jha
Zhe-Sheng Chen
Vijay Tripathi
José M. Pérez de la Lastra
author_sort Uttpal Anand
title Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
title_short Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
title_full Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
title_fullStr Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
title_full_unstemmed Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
title_sort potential therapeutic targets and vaccine development for sars-cov-2/covid-19 pandemic management: a review on the recent update
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2021-06-01
description Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID-19) worldwide. Wuhan, a city in China became the epicenter of the outbreak of COVID-19 in December 2019. The disease was declared a pandemic globally by the World Health Organization (WHO) on 11 March 2020. SARS-CoV-2 is a beta CoV of the Coronaviridae family which usually causes respiratory symptoms that resemble common cold. Multiple countries have experienced multiple waves of the disease and scientific experts are consistently working to find answers to several unresolved questions, with the aim to find the most suitable ways to contain the virus. Furthermore, potential therapeutic strategies and vaccine development for COVID-19 management are also considered. Currently, substantial efforts have been made to develop successful and safe treatments and SARS-CoV-2 vaccines. Some vaccines, such as inactivated vaccines, nucleic acid-based, and vector-based vaccines, have entered phase 3 clinical trials. Additionally, diverse small molecule drugs, peptides and antibodies are being developed to treat COVID-19. We present here an overview of the virus interaction with the host and environment and anti-CoV therapeutic strategies; including vaccines and other methodologies, designed for prophylaxis and treatment of SARS-CoV-2 infection with the hope that this integrative analysis could help develop novel therapeutic approaches against COVID-19.
topic COVID-19
vaccine
therapeutic targets
peptide
antibodies
treatment
url https://www.frontiersin.org/articles/10.3389/fimmu.2021.658519/full
work_keys_str_mv AT uttpalanand potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate
AT shwetajakhmola potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate
AT omkarindari potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate
AT hemchandrajha potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate
AT zheshengchen potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate
AT vijaytripathi potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate
AT josemperezdelalastra potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate
_version_ 1721353126358810624